# Weight Loss FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/weight-loss

> 8 upcoming FDA catalysts in weight Loss: VK2735 (VKTX) on July 2027 (primary completion); VK2735 (VKTX) on Jul to Oct 2027 (topline data readout); VK2735 (VKTX) on July 2027 (primary completion); VK2735 (VKTX) on Jul to Oct 2027 (topline data readout); and 4 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 24, 2025 | [VK2735 primary completion](https://sec-api.dev/pdufa/vk2735) | VKTX | Weight Loss | completed | "NCT06828055 (VK2735 for Weight Management Phase 2 (Venture Oral Dosing)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06828055)) |
| July 2027 | [VK2735 primary completion](https://sec-api.dev/pdufa/vk2735) | VKTX | Weight Loss | scheduled | "NCT07104383 (VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-01 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07104383)) |
| Jul to Oct 2027 | [VK2735 topline data readout](https://sec-api.dev/pdufa/vk2735) | VKTX | Weight Loss | scheduled | "NCT07104383 (VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-01 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07104383)) |
| July 2027 | [VK2735 primary completion](https://sec-api.dev/pdufa/vk2735) | VKTX | Weight Loss | scheduled | "NCT07104500 (VK2735 for Weight Management Phase 3): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-01 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07104500)) |
| Jul to Oct 2027 | [VK2735 topline data readout](https://sec-api.dev/pdufa/vk2735) | VKTX | Weight Loss | scheduled | "NCT07104500 (VK2735 for Weight Management Phase 3): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-01 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07104500)) |
| July 2028 | [VK2735 primary completion](https://sec-api.dev/pdufa/vk2735) | VKTX | Weight Loss | scheduled | "NCT07868835 (Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07868835)) |
| Jul to Oct 2028 | [VK2735 topline data readout](https://sec-api.dev/pdufa/vk2735) | VKTX | Weight Loss | scheduled | "NCT07868835 (Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07868835)) |
| October 2028 | [Vk2735 oral primary completion](https://sec-api.dev/pdufa/vk2735-oral) | VKTX | Weight Loss | scheduled | "NCT07868939 (Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07868939)) |
| Oct 2028 to Jan 2029 | [Vk2735 oral topline data readout](https://sec-api.dev/pdufa/vk2735-oral) | VKTX | Weight Loss | scheduled | "NCT07868939 (Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07868939)) |

## Drugs

- [VK2735](https://sec-api.dev/pdufa/vk2735) (VKTX)
- [Vk2735 oral](https://sec-api.dev/pdufa/vk2735-oral) (VKTX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/weight-loss.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Weight Loss FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/weight-loss

```bibtex
@misc{secapidev_indications_weight_loss_20261116,
  title        = {Weight Loss FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/weight-loss}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_weight_loss_20261116","title":"Weight Loss FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/weight-loss","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
